CTIS2024-511023-34-00招募中1 期
AIPAC-003: A randomized, double-blind, placebo-controlled Phase 3 trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following an open-label dose optimization - IMP321-P016
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Immutep
- 入组人数
- 586
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1. Able to give written informed consent and to comply with the protocol. Note: signed and dated informed consent must be obtained prior to any protocol related procedure., 10. Resolution of toxicity of prior therapy to grade <2 (except for transaminases in the presence of liver metastases and for alopecia where grade 2 is allowed)., 11. Patients who are HBsAg positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization., 12. Patients with a history of HCV infection are eligible if HCV viral load is undetectable at screening., 13. HIV infected patients must be on antiretroviral therapy and have a well-controlled HIV infection/disease defined as: a. Patients on ART must have a CD4+ T-cell count >350 cells/mm3 at time of screening. b. Patients on ART must have achieved and maintained virologic suppression defined as confirmed HIV RNA level below 50 copies/mL or the lower limit of qualification (below the limit of detection) using the locally available assay at the time of screening and for at least 12 weeks prior to screening. c. Patients on ART must have been on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks prior to cycle 1 day 1., 14. Laboratory criteria: a. Total white cell count =3 x 10^9/L b. Platelet count =100 x 10^9/L c. Hemoglobin =9 g/dL or 5.58 mmol/L d. Absolute Neutrophil Count (ANC) =1.5 x 10^9/L e. Estimated glomerular filtration rate by CKD-EPI >30 mL/min f. Total bilirubin =20 µmol/L, except for familial cholemia (Gilbert's disease) g. Serum ASAT and ALAT =3 times ULN or =5 times ULN if liver metastases are present. Please refer to the protocol for the full inclusion criteria with notes., 2. Metastatic HR+ (estrogen receptor positive and/or progesterone receptor positive) or hormone receptor negative (HR-), and HER2- neg/low breast adenocarcinoma, histologically proven by biopsy last available tumor tissue (primary tumor and/or a metastasis; metastasis preferred)., 3. Patients with HR+ MBC who progressed on or after =1 line of endocrine based therapy and are indicated to receive paclitaxel chemotherapy for metastatic disease, in line with locally applicable treatment guidelines and local standard of care. Meeting any of below conditions: a. Primary endocrine resistance: recurrence/relapse =2 years after the start of adjuvant endocrine therapy for early breast cancer, or progression within 6 months of 1st line endocrine based therapy for metastatic breast cancer. b. Secondary endocrine resistance: recurrence/relapse >2 years after starting adjuvant endocrine based therapy, recurrence/relapse <12 months of finishing adjuvant endocrine based therapy or progression after >6 months of endocrine based therapy for metastatic breast cancer., 4. Patients with TNBC who are indicated to receive paclitaxel chemotherapy without anti-PD-1/PD-L1 therapy in the 1st line setting for metastatic disease, in line with locally applicable treatment guidelines and local standard of care., 5. Dose optimization lead-in: Female of age 18 years-of-age or older. Phase 3: Female or male of age 18 years-of-age or older., 6. All patients of childbearing potential must have a negative highly sensitive pregnancy test at screening and agree to use a highly effective method for contraception according to the EU Clinical Trial Facilitation Group guidance from time of trial entry until at least 6 months after the last administration
排除标准
- •1. Prior chemotherapy for metastatic breast adenocarcinoma., 10. Women who are pregnant or lactating., 11. Serious intercurrent infection treated with parenteral antibiotics within 4 weeks prior to first dose of trial treatment., 12. QTcF >480 ms, family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes (TdP)., 13. Uncontrolled electrolyte disorders of grade 2 or higher severity that may worsen the effects of a QTc-prolonging drug (e.g., hypocalcemia, hypokalemia, hypomagnesemia)., 14. Evidence of severe or uncontrolled cardiac disease within 6 months prior to first dose of trial treatment including: myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of NCI CTCAE version 5.0 Grade =2, atrial fibrillation, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (NYHA III-IV), cerebrovascular accident including transient ischemic attack, ventricular arrhythmias requiring medication or symptomatic pulmonary embolism., 15. Active acute or chronic infection (exceptions are defined in Incl. crit. #11-13)., 16. HIV-infected patients with a history of Kaposi sarcoma and/or Multicentric Castleman Disease., 17. Active or past autoimmune disease requiring systemic immunosuppressive therapy in the past 2 years. Replacement therapy is allowed., 18. Any condition requiring continuous systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 4 weeks prior to first dose of trial treatment. Inhaled or topical steroids and physiological replacement doses of up to 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease., 19. Life threatening illness unrelated to cancer., 2. Patients with HR+ MBC who have received <1 line of ET based therapy in the metastatic setting., 20. Previous malignancies within the last three years other than breast cancer, except successfully treated squamous cell carcinoma of the skin, superficial bladder cancer, in situ carcinoma of the cervix and tamoxifenrelated endometrial cancer definitively treated with hysterectomy., 21. Patients with prior organ or stem cell transplantation., 22. Live vaccine within 30 days of planned C1D1. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette–Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed., 23. Patients treated with systemic immune stimulatory agents (excluding vaccines) within 6 weeks or five half-lives of the drug prior to first administration of trial treatment., 24. History of severe allergic episodes and/ or Quincke's oedema., 25. Known hypersensitivity to any of the components of the trial agents., 26. Participation in another interventional clinical trial with last trial treatment given within 4 weeks prior to C1D1, with intent other than covered by Exclusion criterion #8., 27. Any current disorder that would impede the patient's ability to provide informed consent or to comply with the protocol, or in the clinical judgement of the Investigator, the patient is unsuitable for participation in this trial for any reason., 28. Persons with any kind of depend
研究者
相似试验
进行中（未招募）
1 期
A trial to assess the safety and efficacy of UX007 in patients with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)Glucose Transporter Type 1 deficiency syndromeMedDRA version: 17.1 Level: HLGT Classification code 10039911 Term: Seizures (incl subtypes) System Organ Class: 10029205 - Nervous system disordersEUCTR2013-003771-35-GBltragenyx Pharmaceutical Inc36
进行中（未招募）
1 期
Safety and effectiveness of BMS-986263 in adults with compensated cirrhosis (liver disease) from nonalcoholic steatohepatitis (NASH).Compensated Cirrhosis from Nonalcoholic Steatohepatitis (NASH)MedDRA version: 20.0Level: HLTClassification code 10019669Term: Hepatic fibrosis and cirrhosisSystem Organ Class: 100000004871MedDRA version: 20.1Level: LLTClassification code 10064844Term: Compensated cirrhosisSystem Organ Class: 100000004871EUCTR2019-003932-22-DEBristol-Myers Squibb International Corporation270
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110mcg in Adult and Adolescent Subjects 12 years of Age and Older with Perennial Allergic Rhinitis (PAR)Perennial Allergic Rhinitis (PAR) in adults and children of 12 years and older.MedDRA version: 9.1Level: LLTClassification code 10034382Term: Perennial allergic rhinitisEUCTR2007-006562-15-EEGlaxoSmithKline Research & Development Ltd288
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Vasomotor/Idiopathic RhinitisVasomotor/Idiopathic RhinitisEUCTR2004-004744-43-NOGlaxoSmithKline Research & Development Ltd347
进行中（未招募）
1 期
Baricitinib in Patients with COVID-19 InfectioCOVID-19 infectionMedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-001517-21-DEEli Lilly and Company1,400